Florida doctor pleads guilty to role in conspiracy to control cancer resources

The former president and founder of Florida Cancer Specialists & Research Institute (FCS), an oncology provider network, has entered a guilty plea in connection with a conspiracy related to the allocation of cancer treatments in southwest Florida.

According to a release from the U.S. Department of Justice, court documents filed in the U.S. District Court in Ft. Myers show William Harwin, MD, was involved in collusion, wherein chemotherapy drugs were directed to FCS, while radiation treatments were designated for another oncology company. This severely limited the choices available to patients in need of life-saving cancer care in Lee, Collier, and Charlotte Counties of Florida from 1999 until September 2016.

Harwin admited to his role in the conspiracy and admited to violating Section One of the Sherman Act – an antitrust regulation.

“This long-running criminal conspiracy denied cancer patients access to a competitive marketplace for lifesaving oncology treatments,” Emma Burnham of the Justice Department’s antitrust division said in a statement. “The antitrust division will not hesitate to prosecute health care providers who choose profits over patients.”

FCS was also charged in April 2020 for its role in the same antitrust conspiracy. The company agreed to a deferred prosecution arrangement, wherein FCS acknowledged its involvement, leading to a $100 million criminal penalty and cooperation with the ongoing investigation of Harwin.

The court will set a date for sentencing Harwin sometime in 2023. 

Harwin founded FCS in 1984, and his profile on the company website says he is "passionate about ensuring that patients have convenient access to world-class oncology care close to home."

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”